Matinas BioPharma
MTNB
24 hedge funds and large institutions have $254K invested in Matinas BioPharma in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.
53% more capital invested
Capital invested by funds: $166K → $254K (+$87.7K)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
0.86% less ownership
Funds ownership: 6.29% → 5.43% (-0.86%)
4% less funds holding
Funds holding: 25 → 24 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.41K |
| 2 |
Renaissance Technologies
New York
|
+$1.69K |
| 3 |
Raymond James Financial
St Petersburg,
Florida
|
+$234 |
| 4 |
Jones Financial Companies
Des Peres,
Missouri
|
+$44 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$4 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$13.3K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$10.9K |
| 3 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
-$4.53K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.12K |
| 5 |
JP Morgan Chase
New York
|
-$470 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TSS
26
Two Sigma Securities
New York
| – | -$10.9K | -20,974 | Closed |
|
|
27
JP Morgan Chase
New York
| – | -$470 | -904 | Closed |
|
|
NA
28
NewEdge Advisors
New Orleans,
Louisiana
| – | -$1 | -1 | Closed |
|
MTNB Hedge Fund Activity: Q2 2025 in Review
24 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2025, worth a combined $254K — up 53% from $166K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of MTNB and 3 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 4 added.
The largest buyer was Geode Capital Management, adding an estimated $6.41K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $13.3K sold.
- 24 institutional investors held Matinas BioPharma (MTNB) as of Q2 2025, down from 25 in Q1 2025.
- Funds reported $254K of Matinas BioPharma stock for Q2 2025, up 53% quarter-over-quarter.
- 3 funds opened new Matinas BioPharma positions in Q2 2025 and 4 closed out, a net change of -1 holder.
- The largest Matinas BioPharma buyer in Q2 2025 was Geode Capital Management, an estimated $6.41K added.
- The largest Matinas BioPharma seller in Q2 2025 was Susquehanna International Group, an estimated $13.3K sold.
Based on aggregated 13F filings for Q2 2025.